|
|
 |
 |
|
|
Featured Company News
Health Discovery Corporation (OTCBB: HDVY) - SAVANNAH, Ga.--(BUSINESS WIRE)-- Health Discovery Corporation today announced that it is in discussions to license its recently discovered and validated prostate cancer biomarkers. The biomarkers were discovered using Health Discovery Corporations's patented Support Vector Machine (SVM) discovery tools.
These biomarkers have been shown to accurately separate high-grade prostate cancers -- the most malignant form of prostate cancer -- from less malignant grades, with a high degree of accuracy. This ability would allow physicians to tailor prostate cancer treatment to a patient's specific type or grade of cancer -- resulting in significant cost savings by minimizing unnecessary or overly aggressive treatments as well as eliminating the adverse effects that invariably accompany unnecessary treatments. These new prostate cancer biomarkers have been patent protected by Health Discovery Corporation and claims in the patent application are directed to each new set of biomarkers and their uses in screening, diagnosis and treatment of prostate disease.
Profile >
More News >
|
|
|
 |
|
